About Septin-2
Septin-2 (SEPTIN2) is a protein
from Homo sapiens identified by UniProt accession
Q15019, 361 residues long.
MolForge cross-references it against 0 known binders and
159 disease associations.
Target properties
| Protein name | Septin-2 |
|---|
| UniProt accession | Q15019 |
|---|
| Gene | SEPTIN2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 361 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (159)
Diseases linked to this target (Open Targets).
- balding measurement · score 0.29
- alkaline phosphatase measurement · score 0.28
- C-reactive protein measurement · score 0.26
- urate measurement · score 0.26
- apolipoprotein B measurement · score 0.26
- serum albumin measurement · score 0.25
- serum gamma-glutamyl transferase measurement · score 0.25
- BMI-adjusted waist circumference · score 0.24
- calcium measurement · score 0.22
- eosinophil percentage of leukocytes · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15019-F1 | alphafold | PREDICTED | 81.82 | — |
Amino-acid sequence (361 residues)
MSKQQPTQFI NPETPGYVGF ANLPNQVHRK SVKKGFEFTL MVVGESGLGK STLINSLFLT DLYPERVIPG AAEKIERTVQ IEASTVEIEE RGVKLRLTVV DTPGYGDAIN CRDCFKTIIS YIDEQFERYL HDESGLNRRH IIDNRVHCCF YFISPFGHGL KPLDVAFMKA IHNKVNIVPV IAKADTLTLK ERERLKKRIL DEIEEHNIKI YHLPDAESDE DEDFKEQTRL LKASIPFSVV GSNQLIEAKG KKVRGRLYPW GVVEVENPEH NDFLKLRTML ITHMQDLQEV TQDLHYENFR SERLKRGGRK VENEDMNKDQ ILLEKEAELR RMQEMIARMQ AQMQMQMQGG DGDGGALGHH V
Explore Septin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets